Compare HOWL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOWL | NSRX |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 63.4M |
| IPO Year | 2021 | 2025 |
| Metric | HOWL | NSRX |
|---|---|---|
| Price | $0.61 | $7.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $6.50 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 935.7K | 5.8K |
| Earning Date | 11-04-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $5.90 |
| 52 Week High | $2.38 | $9.99 |
| Indicator | HOWL | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | N/A |
| Support Level | $0.59 | N/A |
| Resistance Level | $0.74 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 8.02 | 0.00 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.